Summary
The AI statements provided are about pricing, insurance, and patient assistance program details, none of which are supported or discussed in the provided FDA label excerpts; therefore, label alignment cannot be established and is largely unsupported with respect to labeling content.
Category Scores
Accurate Statements
Unsupported Statements
Without insurance, a single pre-filled syringe of Dupixent can cost several hundred dollars.
No pricing or cost-without-insurance statements are present in the provided label excerpts.
A multi-dose pen of Dupixent can cost over a thousand dollars.
No pricing or product cost statements are present in the provided label excerpts.
One estimate places the retail price of a 300 mg pre-filled syringe of Dupixent at around $3,600 to $3,700.
No pricing or dollar-amount estimates are present in the provided label excerpts.
The retail price of Dupixent is a list price.
The provided label excerpts do not discuss retail/list pricing definitions.
Most patients do not pay the list retail price of Dupixent directly.
No statements about patient payment patterns or list price payment are present in the provided label excerpts.
Pharmaceutical companies often offer patient assistance programs and co-pay cards to help reduce out-of-pocket expenses for eligible individuals.
No patient assistance/co-pay card statements are present in the provided label excerpts.
Insurance plans significantly influence Dupixent’s price.
No discussion of insurance influence on price is present in the provided label excerpts.
Coverage levels and co-pays for Dupixent vary widely among different policies and providers.
No discussion of coverage levels/co-pays variability is present in the provided label excerpts.
Sanofi offers resources to help patients understand their insurance coverage and potential financial assistance options.
No company/program resources about insurance or financial assistance are present in the provided label excerpts.
Sanofi offers the Dupixent MyWay program.
No patient support program (e.g., Dupixent MyWay) is mentioned in the provided label excerpts.
The Dupixent MyWay program provides support services for patients prescribed Dupixent.
No patient support program services are mentioned in the provided label excerpts.
The Dupixent MyWay program can include co-pay assistance for commercially insured patients.
No co-pay assistance program details are mentioned in the provided label excerpts.
The Dupixent MyWay program helps patients navigate insurance and access the medication.
No program description about navigating insurance/access is mentioned in the provided label excerpts.
Eligibility criteria apply for the Dupixent MyWay program.
No program eligibility criteria are mentioned in the provided label excerpts.
Information regarding the specific patent expiration dates for Dupixent is available through resources like DrugPatentWatch.com.
No patent-expiration information or references to external websites are present in the provided label excerpts.
DrugPatentWatch.com tracks patent exclusivity for various medications, including Dupixent.
No mention of DrugPatentWatch.com or patent-tracking sources is present in the provided label excerpts.
Patent information is crucial for understanding when generic versions of a drug might become available, potentially impacting future pricing.
No discussion of patents/generics/future pricing is present in the provided label excerpts.
Contradictions
Important Omissions
The provided AI statements did not include any FDA-label elements (e.g., indications, dosage, contraindications, warnings/precautions, administration instructions, adverse reactions, or relevant specific population guidance) that could be evaluated against the supplied label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The AI statements focus on cost/insurance/patient assistance and patent-tracking resources; these are not addressed in the supplied label excerpts. No safety-critical dosing, contraindication, or warning claims were made in the provided statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Statements about price, insurance, and specific patient-assistance/patent resources are not supported or mentioned in the provided FDA label excerpts.
Suggested Improvement
Limit claims to what is actually contained in the FDA-approved prescribing information excerpts (e.g., indications, dosing principles, contraindications, warnings such as hypersensitivity and vaccination guidance, and relevant population statements). Do not assert or describe pricing, insurance effects, or specific third-party/company programs unless included in the provided label content.